Diabetes & Metabolism Journal

Sun Woo Kim (Kim SW)

3 Articles

Effect on Glycemic, Blood Pressure, and Lipid Control according to Education Types: Mi-Ju Choi, Seung-Hyun Yoo, Kum-Rae Kim, Yoo-Mi Bae, Sun-Hee Ahn, Seong-Shin Kim, Seong-Ah Min, Jin-Sun Choi, Seung-Eun Lee, Yeo-Jin Moon, Eun Jung Rhee, Cheol-Young Park, Won Young Lee, Ki Won Oh, Sung Woo Park, Sun Woo Kim; Diabetes Metab J. 2011;35(6):580-586. Published online December 26, 2011; DOI: https://doi.org/10.4093/dmj.2011.35.6.580

56,054 View
40 Download
5 Crossref

Background

Diabetes self-management education and reinforcement are important for effective management of the disease. We investigated the effectiveness of interactive small-group education on glycemic, blood pressure, and lipid levels.

Methods

For this study, 207 type 2 diabetes patients with suboptimal glycemic control (HbA1c levels >6.5%) were enrolled. The conventional education group received an existing education program from April to November in 2006, and the interactive education group received a new small-group education program from December 2006 to July 2007. The two groups were comparatively analyzed for changes in blood sugar, glycated hemoglobin, lipid, and blood pressure at baseline, 3, 6, and 12 months and the proportion of patients achieving target goals at 12 months.

Results

After 12 months of follow-up, HbA1c levels in the interactive education group were significantly lower than in the conventional education group (6.7% vs. 6.4%, P<0.001). Fasting and 2 hour postprandial glucose concentrations, total cholesterol, and low density lipoprotein cholesterol were significantly lower in the interactive education group than in the conventional education group. The proportion of patients that achieved target goals was significantly higher in the interactive education group.

Conclusion

The small-group educational method improved and re-established the existing group educational method. This finding suggests that the importance of education appears to be related to the method by which it is received rather than the education itself. Thus, the use of small-group educational methods to supplement existing educational methods established for diverse age levels should be considered in the future.

Citations

Citations to this article as recorded by

The Effectiveness of Multidisciplinary Team-Based Education in the Management of Type 2 Diabetes
Jong Ho Kim, Yun Jeong Nam, Won Jin Kim, Kyung Ah Lee, A Ran Baek, Jung Nam Park, Jin Mi Kim, Seo Young Oh, Eun Heui Kim, Min Jin Lee, Yun Kyung Jeon, Bo Hyun Kim, In Joo Kim, Yong Ki Kim, Sang Soo Kim
The Journal of Korean Diabetes.2018; 19(2): 119. CrossRef
Diabetes Camp as Continuing Education for Diabetes Self-Management in Middle-Aged and Elderly People with Type 2 Diabetes Mellitus
So Young Park, Sun Young Kim, Hye Mi Lee, Kyu Yeon Hur, Jae Hyeon Kim, Moon-Kyu Lee, Kang-Hee Sim, Sang-Man Jin
Diabetes & Metabolism Journal.2017; 41(2): 99. CrossRef
Impact of ENPP1 K121Q on Change of Insulin Resistance after Web-Based Intervention in Korean Men with Diabetes and Impaired Fasting Glucose
Ji Yeon Kang, Sook Hee Sung, Yeon Ju Lee, Tae In Choi, Seung Jin Choi
Journal of Korean Medical Science.2014; 29(10): 1353. CrossRef
It's Still Not Too Late to Make a Change: Current Status of Glycemic Control in Korea
Sang Yong Kim
Diabetes & Metabolism Journal.2014; 38(3): 194. CrossRef
Education as Prescription for Patients with Type 2 Diabetes Mellitus: Compliance and Efficacy in Clinical Practice
Mi Yeon Kim, Sunghwan Suh, Sang-Man Jin, Se Won Kim, Ji Cheol Bae, Kyu Yeon Hur, Sung Hye Kim, Mi Yong Rha, Young Yun Cho, Myung-Shik Lee, Moon Kyu Lee, Kwang-Won Kim, Jae Hyeon Kim
Diabetes & Metabolism Journal.2012; 36(6): 452. CrossRef

Retrospective Analysis on the Efficacy, Safety and Treatment Failure Group of Sitagliptin for Mean 10-Month Duration: Won Jun Kim, Cheol-Young Park, Eun Haeng Jeong, Jeong Youn Seo, Ji Soo Seol, Se Eun Park, Eun Jung Rhee, Won Young Lee, Ki Won Oh, Sung Woo Park, Sun Woo Kim; Diabetes Metab J. 2011;35(3):290-297. Published online June 30, 2011; DOI: https://doi.org/10.4093/dmj.2011.35.3.290

4,777 View
34 Download
9 Crossref

Abstract PDF PubReader

Background

To investigate the clinical results of sitagliptin (SITA) and the characteristics of the treatment failure group or of low responders to SITA.

Methods

A retrospective study of type 2 diabetic patients reviewed 99 cases, including 12 treatment failure cases, who stopped SITA because of worsening patients' condition, and 87 cases, who continued treatment over five visits (total 9.9±10.1 months) after receiving the prescription of SITA from December 2008 to June 2009. Subjects were classified as five groups administered SITA as an initial combination with metformin (MET), add-on to metformin or sulfonylurea, and switching from sulfonylurea or thiazolidinedione. The changes in HbA1c level from the first to last visit (ΔHbA1c) in treatment maintenance group were subanalyzed.

Results

The HbA1c level was significantly reduced in four groups, including initial coadministration of SITA with metformin (ΔHbA1c=-1.1%, P<0.001), add-on to MET (ΔHbA1c=-0.6%, P=0.017), add-on to sulfonylurea (ΔHbA1c=-0.5%, P<0.001), and switching from thiazolidinedione (ΔHbA1c=-0.3%, P=0.013). SITA was noninferior to sulfonlyurea (ΔHbA1c=-0.2%, P=0.63). There was no significant adverse effect. The treatment failure group had a longer diabeties duration (P=0.008), higher HbA1c (P=0.001) and fasting plasma glucose (P=0.003) compared to the maintenance group. Subanalysis on the tertiles of ΔHbA1c showed that low-response to SITA (tertile 1) was associated with a longer diabetes duration (P=0.009) and lower HbA1c (P<0.001).

Conclusion

SITA was effective and safe for use in Korean type 2 diabetic patients. However, its clinical responses and long-term benefit-harm profile is yet to be established.

Citations

Citations to this article as recorded by

Development of a 13C Stable Isotope Assay for Dipeptidyl Peptidase-4 Enzyme Activity A New Breath Test for Dipeptidyl Peptidase Activity
Roger Yazbeck, Simone Jaenisch, Michelle Squire, Catherine A. Abbott, Emma Parkinson-Lawrence, Douglas A. Brooks, Ross N. Butler
Scientific Reports.2019;[Epub] CrossRef
Characterization of changes in HbA1c in patients with and without secondary failure after metformin treatments by a population pharmacodynamic analysis using mixture models
Yoko Tamaki, Kunio Maema, Makoto Kakara, Masato Fukae, Ryoko Kinoshita, Yushi Kashihara, Shota Muraki, Takeshi Hirota, Ichiro Ieiri
Drug Metabolism and Pharmacokinetics.2018; 33(6): 264. CrossRef
Effects of 6-Month Sitagliptin Treatment on Insulin and Glucagon Responses in Korean Patients with Type 2 Diabetes Mellitus
Hae Kyung Yang, Borami Kang, Seung-Hwan Lee, Hun-Sung Kim, Kun-Ho Yoon, Bong-Yun Cha, Jae-Hyoung Cho
Diabetes & Metabolism Journal.2015; 39(4): 335. CrossRef
Clinical Characteristics and Metabolic Predictors of Rapid Responders to Dipeptidyl Peptidase-4 Inhibitor as an Add-on Therapy to Sulfonylurea and Metformin
Ye An Kim, Won Sang Yoo, Eun Shil Hong, Eu Jeong Ku, Kyeong Seon Park, Soo Lim, Young Min Cho, Kyong Soo Park, Hak Chul Jang, Sung Hee Choi
Diabetes & Metabolism Journal.2015; 39(6): 489. CrossRef
Letter: Predictive Factors for Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J2015;39:342-7)
Ye An Kim
Diabetes & Metabolism Journal.2015; 39(5): 444. CrossRef
Optimal Candidates for the Switch from Glimepiride to Sitagliptin to Reduce Hypoglycemia in Patients with Type 2 Diabetes Mellitus
Hyun Min Kim, Jung Soo Lim, Byung-Wan Lee, Eun-Seok Kang, Hyun Chul Lee, Bong-Soo Cha
Endocrinology and Metabolism.2015; 30(1): 84. CrossRef
One-year real-life efficacy of sitagliptin revealed importance of concomitant pioglitazone use in Japanese patients with type 2 diabetes mellitus
Ayako Suzuki, Nakayuki Yoshimura, Yamato Mashimo, Maiko Numakura, Yuko Fujimaki, Tomomi Maeda, Toshio Ishikawa, Shin Fujimori, Kazuhiro Eto
Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2013; 7(3): 143. CrossRef
Clinical Characteristics of the Responders to Dipeptidyl Peptidase-4 Inhibitors in Korean Subjects with Type 2 Diabetes
Tae Jung Oh, Hye Seung Jung, Jae Hyun Bae, Yeong Gi Kim, Kyeong Seon Park, Young Min Cho, Kyong Soo Park, Seong Yeon Kim
Journal of Korean Medical Science.2013; 28(6): 881. CrossRef
Factors predicting therapeutic efficacy of combination treatment with sitagliptin and metformin in type 2 diabetic patients: the COSMETIC study
Soo Lim, Jee Hyun An, Hayley Shin, Ah Reum Khang, Yenna Lee, Hwa Young Ahn, Ji Won Yoon, Seon Mee Kang, Sung Hee Choi, Young Min Cho, Kyong Soo Park, Hak Chul Jang
Clinical Endocrinology.2012; 77(2): 215. CrossRef

Triple Combination Therapy Using Metformin, Thiazolidinedione, and a GLP-1 Analog or DPP-IV Inhibitor in Patients with Type 2 Diabetes Mellitus: Sun Woo Kim; Korean Diabetes J. 2010;34(6):331-337. Published online December 31, 2010; DOI: https://doi.org/10.4093/kdj.2010.34.6.331

3,658 View
42 Download
8 Crossref

Abstract PDF PubReader

Although there is no HbA1c threshold for cardiovascular risk, the American Diabetic Association-recommended goal of HbA1c < 7.0% appears to be unacceptably high. To achieve an optimal HbA1c level goal of 6.0% or less, a high dosage of sulfonylureas and insulin would be required; the trade-off would be the common adverse effects of hypoglycemia and weight gain. In contrast, hypoglycemia is uncommon with insulin sensitizers and GLP-1 analogs, allowing the physician to titrate these drugs to maximum dosage to reduce HbA1c levels below 6.0% and they have been shown to preserve β-cell function. Lastly, weight gain is common with sulfonylurea and insulin therapy, whereas GLP-1 analogs induce weight loss and offset the weight gain associated with TZDs. A treatment paradigm shift is recommended in which combination therapy is initiated with diet/exercise, metformin (which has antiatherogenic effects and improves hepatic insulin sensitivity), a TZD (which improves insulin sensitivity and preserves β-cell function with proven durability), and a GLP-1 analog (which improves β, α-cell function and promotes weight loss) or a dipeptidyl peptidase IV inhibitor in patients with type 2 diabetes mellitus.

Citations

Citations to this article as recorded by

Antidiabetic Agents and Bone Quality: A Focus on Glycation End Products and Incretin Pathway Modulations
Muthanna K. Zaki, Mohammed N. Abed, Fawaz A. Alassaf
Journal of Bone Metabolism.2024; 31(3): 169. CrossRef
Design, synthesis and evaluation of l-quebrachitol derivatives against α-glycosidase
Maoying Zhang, Xinjie Liang, Pengcheng Cai, Qixun Feng, Yongsong Chen, Xiaoxi Yu, Kuo Zhang, Xuefei Bao, Guoliang Chen
New Journal of Chemistry.2023; 47(28): 13387. CrossRef
Phase III Study on Efficacy and Safety of Triple Combination (Exenatide/Metformin/Biphasic Insulin Aspart) Therapy for Type 2 Diabetes Mellitus
Ke Su, Chunmei Lv, Zongwen Ji, Yishu Wang, Haifeng Wang, Ying Bai, Yaping Liu
American Journal of Therapeutics.2018; 25(6): e609. CrossRef
A Case Report of Diabetes Mellitus with Herniated Intervertebral Lumbar Discs Improved by Korean Medicine Treatment
Dong-geun Han, A-ryun Choi, You-jin Jung, Ah-hyun Kang, Hye-jin Seo, Jae-yeon Sung, Hyung-chul Lee, Gook-hyun Eom, Woo-sub Song
The Journal of Internal Korean Medicine.2017; 38(5): 828. CrossRef
A crossover study of the combination therapy of metformin and exenatide or biphasic insulin aspart 30 in overweight or obese patients newly diagnosed with type 2 diabetes mellitus
Huibiao Quan, Huachuan Zhang, Weiping Wei, Tuanyu Fang, Daoxiong Chen, Kaining Chen
Experimental and Therapeutic Medicine.2017; 14(4): 3279. CrossRef
Gender-related different effects of a combined therapy of Exenatide and Metformin on overweight or obesity patients with type 2 diabetes mellitus
Huibiao Quan, Huachuan Zhang, Weiping Wei, Tuanyu Fang
Journal of Diabetes and its Complications.2016; 30(4): 686. CrossRef
Bioreducible polymers for therapeutic gene delivery
Young Sook Lee, Sung Wan Kim
Journal of Controlled Release.2014; 190: 424. CrossRef
Managing diabetes in Asia: Overcoming obstacles and the role of DPP-IV inhibitors
Yi-Ming Mu, Anoop Misra, John M.F. Adam, Siew Pheng Chan, Francis C.C. Chow, Elaine Cheeay Cunanan, Chaicharn Deerochanawong, Hak Chul Jang, Nguyen Thy Khue, Wayne H.-H. Sheu, Kevin E.K. Tan
Diabetes Research and Clinical Practice.2012; 95(2): 179. CrossRef

Author index